{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:31:14Z","timestamp":1792096274407,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/onc.2017.326","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T15:05:07Z","timestamp":1506351907000},"page":"341-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy"],"prefix":"10.1038","volume":"37","author":[{"given":"X","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"BFonc2017326_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","volume":"366","author":"F Amant","year":"2005","unstructured":"Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I . Endometrial cancer. Lancet 2005; 366: 491\u2013505.","journal-title":"Lancet"},{"key":"BFonc2017326_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research N Cancer Genome Atlas Research N Kandoth C Cancer Genome Atlas Research N Schultz N Cancer Genome Atlas Research N Cherniack AD Cancer Genome Atlas Research N Akbani R Cancer Genome Atlas Research N Liu Y et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67\u201373.","journal-title":"Nature"},{"key":"BFonc2017326_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","volume":"8","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS . Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011; 8: 261\u2013271.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc2017326_CR4","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015; 21: 4257\u20134261.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017326_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD . Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015; 5: 1137\u20131154.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0140-6736(10)61119-1","volume":"376","author":"SL Chan","year":"2010","unstructured":"Chan SL, Mok T . PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet 2010; 376: 211\u2013213.","journal-title":"Lancet"},{"key":"BFonc2017326_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697\u20131708.","journal-title":"N Engl J Med"},{"key":"BFonc2017326_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154\u20132164.","journal-title":"N Engl J Med"},{"key":"BFonc2017326_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017; 18: 75\u201387.","journal-title":"Lancet Oncol"},{"key":"BFonc2017326_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17: 875\u2013882.","journal-title":"Nat Med"},{"key":"BFonc2017326_CR11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","volume":"22","author":"W Mo","year":"2016","unstructured":"Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 2016; 22: 1699\u20131712.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017326_CR12","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","volume":"23","author":"TM Cardillo","year":"2017","unstructured":"Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM . Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1\/2-wild-type triple-negative breast cancer. Clin Cancer Res 2017; 23: 3405\u20133415.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017326_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","volume":"1","author":"LW Cheung","year":"2011","unstructured":"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011; 1: 170\u2013185.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627\u2013644.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2017326_CR15","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-12-3815","volume":"19","author":"B Weigelt","year":"2013","unstructured":"Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J . PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res 2013; 19: 3533\u20133544.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017326_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccr.2005.01.009","volume":"7","author":"J Puc","year":"2005","unstructured":"Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005; 7: 193\u2013204.","journal-title":"Cancer Cell"},{"key":"BFonc2017326_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","volume":"128","author":"WH Shen","year":"2007","unstructured":"Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157\u2013170.","journal-title":"Cell"},{"key":"BFonc2017326_CR18","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1158\/0008-5472.CAN-09-4295","volume":"70","author":"B McEllin","year":"2010","unstructured":"McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70: 5457\u20135464.","journal-title":"Cancer Res"},{"key":"BFonc2017326_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrclinonc.2011.42","volume":"8","author":"MD Forster","year":"2011","unstructured":"Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011; 8: 302\u2013306.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc2017326_CR20","doi-asserted-by":"publisher","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","volume":"2","author":"KJ Dedes","year":"2010","unstructured":"Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.","journal-title":"Sci Transl Med"},{"key":"BFonc2017326_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","volume":"1","author":"AM Mendes-Pereira","year":"2009","unstructured":"Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315\u2013322.","journal-title":"EMBO Mol Med"},{"key":"BFonc2017326_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1471-2407-14-179","volume":"14","author":"A Miyasaka","year":"2014","unstructured":"Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer 2014; 14: 179.","journal-title":"BMC Cancer"},{"key":"BFonc2017326_CR23","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1535-7163.MCT-13-0572","volume":"12","author":"DM Janzen","year":"2013","unstructured":"Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 2013; 12: 2917\u20132928.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2017326_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550\u2013562.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017326_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon J, Dienstmann R, Serra V, Tabernero J . Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10: 143\u2013153.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc2017326_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015; 15: 7\u201324.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017326_CR27","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug K, Graupera M, Vanhaesebroeck B . Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov 2016; 6: 1090\u20131105.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.1236188","volume":"341","author":"C Bassi","year":"2013","unstructured":"Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013; 341: 395\u2013399.","journal-title":"Science"},{"key":"BFonc2017326_CR29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2: 1036\u20131047.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/2159-8290.CD-13-0230","volume":"4","author":"E Gonzalez-Billalabeitia","year":"2014","unstructured":"Gonzalez-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 2014; 4: 896\u2013904.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2016.07.092","volume":"142","author":"D Wang","year":"2016","unstructured":"Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L et al. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol 2016; 142: 548\u2013556.","journal-title":"Gynecol Oncol"},{"key":"BFonc2017326_CR32","doi-asserted-by":"crossref","first-page":"13153","DOI":"10.18632\/oncotarget.7549","volume":"7","author":"D Wang","year":"2016","unstructured":"Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X et al. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget 2016; 7: 13153\u201313166.","journal-title":"Oncotarget"},{"key":"BFonc2017326_CR33","doi-asserted-by":"publisher","first-page":"e0152584","DOI":"10.1371\/journal.pone.0152584","volume":"11","author":"RJ Cardnell","year":"2016","unstructured":"Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA et al. Activation of the PI3K\/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One 2016; 11: e0152584.","journal-title":"PLoS One"},{"key":"BFonc2017326_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/35056049","volume":"2","author":"DC van Gent","year":"2001","unstructured":"van Gent DC, Hoeijmakers JH, Kanaar R . Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001; 2: 196\u2013206.","journal-title":"Nat Rev Genet"},{"key":"BFonc2017326_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy R, Chun J, Powell SN . BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2011; 12: 68\u201378.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017326_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrm1202","volume":"4","author":"MR Lieber","year":"2003","unstructured":"Lieber MR, Ma Y, Pannicke U, Schwarz K . Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003; 4: 712\u2013720.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc2017326_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/0008-5472.CAN-13-0544","volume":"74","author":"H Cheng","year":"2014","unstructured":"Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 2014; 74: 15\u201323.","journal-title":"Cancer Res"},{"key":"BFonc2017326_CR38","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","volume":"2","author":"A Juvekar","year":"2012","unstructured":"Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048\u20131063.","journal-title":"Cancer Discov"},{"key":"BFonc2017326_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-11-2189","volume":"18","author":"M Fraser","year":"2012","unstructured":"Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2012; 18: 1015\u20131027.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017326_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc2842","volume":"10","author":"TD Bunney","year":"2010","unstructured":"Bunney TD, Katan M . Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010; 10: 342\u2013352.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017326_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140\u2013156.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2017326_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917\u2013921.","journal-title":"Nature"},{"key":"BFonc2017326_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123\u2013134.","journal-title":"N Engl J Med"},{"key":"BFonc2017326_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","volume":"21","author":"T Muranen","year":"2012","unstructured":"Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC et al. Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227\u2013239.","journal-title":"Cancer Cell"},{"key":"BFonc2017326_CR45","doi-asserted-by":"publisher","first-page":"12235","DOI":"10.1038\/ncomms12235","volume":"7","author":"L Li","year":"2016","unstructured":"Li L, Shi L, Yang S, Yan R, Zhang D, Yang J et al. SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. Nat Commun 2016; 7: 12235.","journal-title":"Nat Commun"},{"key":"BFonc2017326_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0091-679X(08)60569-5","volume":"35","author":"CV Johnson","year":"1991","unstructured":"Johnson CV, Singer RH, Lawrence JB . Fluorescent detection of nuclear RNA and DNA: implications for genome organization. Methods Cell Biol 1991; 35: 73\u201399.","journal-title":"Methods Cell Biol"},{"key":"BFonc2017326_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/2159-8290.CD-11-0325","volume":"2","author":"FC Martins","year":"2012","unstructured":"Martins FC, De S, Almendro V, Gonen M, Park SY, Blum JL et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2012; 2: 503\u2013511.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2017326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017326","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:01:57Z","timestamp":1684472517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFonc2017326"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.326","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"assertion":[{"value":"14 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}